keyboard_arrow_up

Antibiotics Partnering Terms and Agreements

Antibiotics Partnering Terms and Agreements is a new market research publication announced by Reportstack. The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value
 
The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 
 
This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
 
Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Penicillin
Quinolones
Sulfonamides
Tetracycline
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                
This report contains over 150 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
For example, analyzing actual company deals and agreements allows assessment of the following:
 
What is actually granted by the agreement to the partner company?
                
What exclusivity is granted?
 
What are the precise rights granted or optioned?
 
What is the payment structure for the deal?
 
How aresalesand payments audited?
 
What is the deal term?
 
How are the key terms of the agreement defined?
 
How are IPRs handled and owned?
 
Who is responsible for commercialization?
 
Who is responsible for development, supply, and manufacture?
 
How is confidentiality and publication managed?
 
How are disputes to be resolved?
 
Under what conditions can the deal be terminated?
 
What happens when there is a change of ownership?
 
What sublicensing and subcontracting provisions have been agreed?
 
Which boilerplate clauses does the company insist upon?
 
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
 
Which jurisdiction does the company insist upon for agreement law?
 
The initial chapters of this report provide an orientation of drug dealmaking and business activities. The report provides an overview of the trends in antibiotics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms, 
a review of the leading antibiotics deals since 2009. Deals are listed by headline value, signed by big pharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract, a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand, a comprehensive listing of the top 50 big biotech companies with deal announced along with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand, provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 
The report also provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009 organized by antibiotics technology focus. The chapter includes deals listed by antibiotics and broken down into individual type of antibiotics- aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicillin, quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2009.
 
In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z , stage of development, deal type and therapy focus, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.
Report scope. Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.
 
                                             
Antibiotics Partnering Terms and Agreements includes:
                                                        
Trends in antibiotics dealmaking in the biopharma industry since 2009
Analysis of antibiotics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibiotics deals
Access to over 150 antibiotics contract documents
The leading antibody deals by value since 2009
Most active antibiotics dealmakers since 2007
The leading antibiotics partnering resources
 
 
In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:
 
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target
 
Antibiotics Partnering Terms and Agreements provides the reader with the following key benefits:
 
In-depth understanding of antibiotic deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibiotics agreements with numerous real life case studies
Comprehensive access to over 150 actual antibiotics contracts entered into by the world’s biopharma companies
Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a antibiotics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals          
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Companies Mentioned: Abbott, Actavis, Astellas, AstraZeneca, Bayer, Eli Lilly, Forest Laboratories, Galderma, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, Shionogi, Teva, Valeant, Warner Chilcott, Biocon, Cubist, Emergent BioSolutions, Galapagos, Optimer, Swedish Orphan Biovitrum, The Medicines Company, ViroPharma, Achaogen, Anacor Pharmaceuticals, ARK Diagnostics, Astellas Pharma, Basilea Pharmaceutica, Bayer, Biocon, Biomedical Advanced Research and Development Authority, Calixa Therapeutics, Colorado State University, Cornerstone Therapeutics, Cubist Pharmaceuticals, CUBRC, Defense Threat Reduction Agency, Department of Health and Human Services, Dipexium Pharmaceuticals, Enanta Pharmaceuticals, Genzyme, GlaxoSmithKline, Intrexon, Melinta Therapeutics, National Institute of Allergy and Infectious Diseases, Optimer Pharmaceuticals, Oragenics, Oscient Pharmaceuticals, Patheon, Polypeptide Laboratory, Prev AbR, RRD International, Sanofi, Synthetic Biologics, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Texas A&M University, The Regents of the University of California, Trius Therapeutics, University of California Berkeley, University of Florida Research Foundation, University of Washington.

To view the table of contents and know more details please visit Antibiotics Partnering Terms and Agreements.